Silverarc Capital Management LLC lessened its holdings in shares of Geron Co. (NASDAQ:GERN - Free Report) by 48.9% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 920,022 shares of the biopharmaceutical company's stock after selling 881,539 shares during the quarter. Silverarc Capital Management LLC owned about 0.15% of Geron worth $3,257,000 at the end of the most recent reporting period.
Other large investors have also recently modified their holdings of the company. SBI Securities Co. Ltd. bought a new position in Geron in the 4th quarter worth approximately $28,000. Rovin Capital UT ADV lifted its position in shares of Geron by 26.9% during the fourth quarter. Rovin Capital UT ADV now owns 17,270 shares of the biopharmaceutical company's stock worth $61,000 after acquiring an additional 3,660 shares in the last quarter. Harvest Investment Services LLC bought a new position in shares of Geron in the fourth quarter worth $61,000. Monterey Private Wealth Inc. purchased a new position in shares of Geron in the fourth quarter valued at $63,000. Finally, Jump Financial LLC purchased a new position in shares of Geron in the fourth quarter valued at $70,000. Hedge funds and other institutional investors own 73.71% of the company's stock.
Geron Price Performance
NASDAQ GERN remained flat at $1.42 during trading hours on Friday. The company's stock had a trading volume of 6,357,119 shares, compared to its average volume of 11,492,344. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89. The firm has a market cap of $904.42 million, a P/E ratio of -4.44 and a beta of 0.66. The firm has a 50-day moving average price of $1.64 and a 200 day moving average price of $2.93. Geron Co. has a twelve month low of $1.17 and a twelve month high of $5.34.
Geron (NASDAQ:GERN - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) EPS for the quarter, hitting the consensus estimate of ($0.04). The firm had revenue of $47.54 million for the quarter, compared to the consensus estimate of $45.29 million. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. On average, sell-side analysts forecast that Geron Co. will post -0.25 EPS for the current fiscal year.
Analyst Ratings Changes
Several research analysts have commented on the company. Stifel Nicolaus cut their target price on Geron from $8.00 to $4.00 and set a "buy" rating for the company in a research note on Thursday, February 27th. Barclays reaffirmed an "overweight" rating and set a $4.00 price objective (down previously from $9.00) on shares of Geron in a research note on Thursday, February 27th. Needham & Company LLC reaffirmed a "buy" rating and set a $5.00 target price on shares of Geron in a report on Wednesday, March 12th. HC Wainwright reissued a "neutral" rating on shares of Geron in a report on Wednesday, March 12th. Finally, Scotiabank decreased their price target on shares of Geron from $6.00 to $4.00 and set a "sector outperform" rating on the stock in a report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Geron presently has an average rating of "Moderate Buy" and an average target price of $5.75.
View Our Latest Analysis on Geron
About Geron
(
Free Report)
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.
Further Reading
Before you consider Geron, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Geron wasn't on the list.
While Geron currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
